Showing 251-260 of 650 results for "".
Taking “picture perfect” before and after photos
https://practicaldermatology.com/topics/practice-management/taking-picture-perfect-before-and-after-photos/19751/You probably know the importance of including before and after photos on your dermatology website. However, you might be wondering how to create a professional looking image gallery without a photographer on call. Check out the latest video from Ekwa Marketing to find out!Get More of the Patients You Want
https://practicaldermatology.com/topics/practice-management/get-more-of-the-patients-you-want/20520/How to use micro-targeted digital marketing to grow your practice.Reputation Management for the Modern Dermatology Practice
https://practicaldermatology.com/topics/practice-management/reputation-management-for-the-modern-dermatology-practice/23511/Word-of-mouth marketing has gone online. Here’s what to know.A Growing Armamentarium for Psoriasis: How to Choose the Right Treatment for Each Patient
https://practicaldermatology.com/topics/psoriasis/a-growing-armamentarium-for-psoriasis-how-to-choose-the-right-treatment-for-each-patient/18214/Erin Boh, MD joins host Joshua Zeichner, MD in this edition of DermTube Journal Club to offer tips for navigating all the new and existing treatment options for patients with moderate to severe psoriasis. With so many effective options on the market, Dr. Boh says it's possible to find the best fit fDupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sApprovals in Psoriasis and Skin Cancer Highlight a Year of Innovation in Skin Disease Management
https://practicaldermatology.com/topics/skin-cancer-photoprotection/approvals-in-psoriasis-and-skin-cancer-highlight-a-year-of-innovation-in-skin-disease-management/21069/After periods of low drug approval rates, the last year brought several new agents to market.Online Reputation Management Update
https://practicaldermatology.com/topics/practice-management/online-reputation-management-update/18658/Protecting your online reputation is crucial to your digital marketing success. If you think it's all about spotting and hiding bad reviews, you're wrong. Learn how to build and protect a stellar online reputation for your dermatology practice and how it will actually boost SEO. The Ekwa Marketing t"Where to Start: Opening and Running a Private Practice" Drs. Jackson and Hooper
https://practicaldermatology.com/youngmd-connect/ymdc-workshops/where-to-start-opening-and-running-a-private-practice-drs-jackson-and-hooper/24544/Explore the essentials of starting and running a private practice in this unique webinar with Drs. Deirdre Hooper and Sarah Jackson. They cover practice setup, marketing, patient acquisition, and operational management, sharing invaluable insights for professional and financial success. To access moAn Exciting Year in Dermatology
https://practicaldermatology.com/topics/psoriasis/an-exciting-year-in-dermatology/19929/From new topicals to novel systemic agents, several treatments may be coming to the market in the next two years, while existing therapies may see label expansions. Bruce Strober, MD, PhD offers a look at new MOAs and the evidence for their use.Checkpoint Blockade for Advanced cSCC: Exploring Newer Options
https://practicaldermatology.com/topics/skin-cancer-photoprotection/checkpoint-blockade-for-advanced-cscc-exploring-newer-options/23487/Two newer systemic options on the market provide hope in the fight against advanced cutaneous squamous cell carcinoma.